Tagrisso Patent Protection
5 patents · AstraZeneca AB
Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 9732058 | Drug substance & product patent | AstraZeneca AB | Jul 25, 2032 | 6.1y left |
| 11524951 | Drug substance & product patent | AstraZeneca AB | Jul 25, 2032 | 6.1y left |
| 8946235 | Drug substance & product patent | AstraZeneca AB | Aug 8, 2032 | 6.1y left |
| 10183020 | Drug product (formulation / method-of-use) patent | AstraZeneca AB | Jan 2, 2035 | 8.5y left |
| 12465608 | Orange Book listed patent | AstraZeneca AB | Nov 26, 2042 | 16.4y left |
Related Drug Patent Expirations
12 patents · earliest expires 2027 · AstraZeneca AB
17 patents · earliest expires 2026 · AstraZeneca AB
9 patents · earliest expires 2033 · Gilead Sciences Inc.
45 patents · earliest expires 2031 · AbbVie Inc.
1 patents · earliest expires 2031 · Eli Lilly and Company
3 patents · earliest expires 2030 · Celgene Corporation
Tagrisso is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for Tagrisso’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.